Funder
Japan Society for Promotion of Science
Publisher
Springer Science and Business Media LLC
Subject
Pharmacology (medical),Cancer Research,Pharmacology,Toxicology,Oncology
Reference31 articles.
1. Garcia J, Hurwitz HI, Sandler AB, Miles D, Coleman RL, Deurloo R, Chinot OL (2020) Bevacizumab (Avastin®) in cancer treatment: a review of 15 years of clinical experience and future outlook. Cancer Treat Rev 86: 102017. https://www.sciencedirect.com/science/article/pii/S0305737220300554
2. EMA (2022) Avastin: European public assessment report product information. https://www.ema.europa.eu/en/documents/product-information/avastin-epar-product-information_en.pdf. Accessed 16 Dec 2022.
3. FDA (2022) Avastin: prescribing information. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/125085s332lbl.pdf. Accessed 16 Dec 2022.
4. Zhu X, Wu S, Dahut WL, Parikh CR (2007) Risks of proteinuria and hypertension with bevacizumab, an antibody against vascular endothelial growth factor: systematic review and meta-analysis. Am J Kidney Dis 49(2): 186–193. https://www.ajkd.org/article/S0272-6386(06)01833-6/pdf
5. Wu S, Kim C, Baer L, Zhu X (2010) Bevacizumab increases risk for severe proteinuria in cancer patients. J Am Soc Nephrol 21(8):1381–1389. https://doi.org/10.1681/ASN.2010020167
Cited by
3 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献